Supernus Inc. (SUPN)
NASDAQ: SUPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SUPN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.94B
- Forward P/E
- 7.15
- EPS (TTM)
- -$0.76
- Dividend yield
- None
- Ex-dividend date
- Nov 3, 2026
- 52-week range
- 25.92 – 42.81
- Day range
- 28.15 – 29.51
- Volume / Avg
- 2.83M / 2.77M
- Beta
- —
- Shares outstanding
- 207.72M
52-week range
SUPN stock today
Shares of Supernus (SUPN) finished higher on Nov 20 at $28.61, a gain of 0.92% or $0.26 per share, versus the S&P 500's 3.70% decline. At this level, SUPN sits near the bottom of its 52-week range of $25.92 to $42.81: 33.2% below the high and 10.4% above the low. SUPN is down 42.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.9%.
Supernus has posted a net loss over the last twelve months (EPS of -$0.76), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Supernus
Company profileSupernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jack A. Khattar M.B.A.
- Headquarters
- Rockville, MD
- Employees
- 827
- IPO year
- 2012
- Website
- supernus.com
Financial highlights
Full financialsIn fiscal 2025, Supernus generated $719.0 million in revenue, up 8.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Supernus reported a net loss of $38.5 million, compared with net income of $73.9 million a year earlier. Gross margin was 89.6% (up from 88.2%) and operating margin -8.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $718.95M | $661.82M | $607.52M | $667.24M | $579.77M |
| Growth | +8.63% | +8.94% | -8.95% | +15.09% | +11.41% |
| Net income | $-38.55M | $73.86M | $1.32M | $60.71M | $53.42M |
| EPS (diluted) | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$54.14+89.23%
- Strong buy 2
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $0.35 vs $0.34
- Surprise
- +2.94%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $8.13
- Ex-dividend date
- Nov 3, 2026
- Pay date
- Nov 6, 2026
SUPN news
All SUPN news- Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical LeaderGlobeNewswire
- Supernus (SUPN) Q3 2026 Earnings Call TranscriptNasdaqSUPN, MKC.V
- Supernus Pharmaceuticals, Inc. Reports Record Third Quarter 2026 Revenues of $226.8 millionNasdaqSUPN, MOG.A
- Supernus Pharmaceuticals GAAP EPS of $0.35 beats by $0.42, revenue of $226.8M beats by $9.24MSeeking Alpha
- Supernus Announces Third Quarter 2026 Financial ResultsGlobeNewswire
- BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View TightenedNasdaqBIIB, SUPN, TGTX
- Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?NasdaqBIIB, PFE, GILD, SUPN
- Supernus Pharmaceuticals Announces FDA Recognition of Seven Years of Orphan-Drug Exclusivity for ONAPGONasdaq
Supernus peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARWRArrowhead Pharmaceuticals Inc. | 41.37 | -5.22% | $5.85B | vs SUPN |
| LGNDLigand Pharmaceuticals Incorporated | 286.85 | -0.03% | $5.74B | vs SUPN |
| GRFSGrifols S.A. ADR | 8.15 | -0.61% | $5.55B | vs SUPN |
| MIRMMirum Pharmaceuticals Inc. | 96.13 | +0.65% | $6.28B | vs SUPN |
| ABVXAbivax SA ADR | 73.20 | -9.24% | $6.41B | vs SUPN |
| BLTEBelite Bio Inc ADR | 127.38 | -15.65% | $5.17B | vs SUPN |
| MANEVeradermics Incorporated | 119.52 | -3.92% | $5.04B | vs SUPN |
| AXSMAxsome Therapeutics Inc. | 129.36 | -4.66% | $6.80B | vs SUPN |
Indexes, lists and sector
Supernus stock FAQ
What is Supernus's stock price today?
SUPN last traded at $28.61 as of Nov 20, 4:00 PM EST, up 0.92% on the day. Prices are delayed at least 15 minutes.
Does Supernus pay a dividend?
Yes. Supernus pays $0.00 per share annually. The most recent dividend of $8.13 had an ex-dividend date of Nov 3, 2026.
Who is Supernus's CEO?
Mr. Jack A. Khattar M.B.A. is the chief executive officer of Supernus Inc., which has about 827 employees.
What is the SUPN 52-week high?
The 52-week high for SUPN is $42.81 and the 52-week low is $25.92. The stock is currently 33.2% below its high.